Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

4 Nov 2016

Abstract excerpt

Abstract Purpose: Using gene-disrupted allogeneic T cells as universal effector cells provides an alternative and potentially improves current chimeric antigen receptor (CAR) T-cell therapy against cancers and infectious diseases. Experimental Design: The CRISPR/Cas9 system has recently emerged as a simple and efficient way for multiplex genome engineering. By combining lentiviral delivery of CAR and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27815355
DOI: 10.1158/1078-0432.ccr-16-1300

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 InhibitionPMID 27815355Read ↗

Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against LeukemiaSemantic proximity Read ↗

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read ↗

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapiesSemantic proximity Read ↗

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapySemantic proximity Read ↗

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapySemantic proximity Read ↗

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapySemantic proximity Read ↗

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cellsSemantic proximity Read ↗

Elucidation of CRISPR-Cas9 Application in Novel Cellular Immunotherapy.Semantic proximity Read ↗

Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome EditingSemantic proximity Read ↗

CRISPR, CAR-T, and NK: Current applications and future perspectivesSemantic proximity Read ↗

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapySemantic proximity Read ↗

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.